{
  "id": 3428615,
  "title": "Why is SK Biopharmaceuticals stock surging today?",
  "url": "https://urgent.news/2026/08/26/why-is-sk-biopharmaceuticals-stock-surging-today",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-26T04:27:23.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/stock-market-news/why-is-sk-biopharmaceuticals-stock-surging-today-93CH-4876250"
  },
  "original_language": "en",
  "account": "SK Biopharmaceuticals stock experienced a significant surge of 10.5% on Wednesday after the company announced a major licensing agreement with Biohaven Bioscience Ireland. The deal grants SK Biopharmaceuticals the rights to the epilepsy drug candidate Opakalim, a range of Kv7 activator compounds, and the Kv7 discovery platform. This acquisition is valued at up to $795 million, with an upfront payment of $400 million, $350 million payable at the time of closing and an additional $50 million due one year later. This transaction represents one of SK Biopharmaceuticals' most substantial pipeline investments to date. The deal comes amidst already-strong commercial momentum for the company. Just the day prior, analysts at Heungkuk Securities had upgraded their rating on SK Bio, giving a Buy rating with a 140,000 KRW price target, citing Cenobamate's 24% year-on-year prescription growth in July and second-quarter consolidated revenue of 247.4 billion KRW - a 40.3% increase from the previous year - as evidence of the company's core epilepsy franchise remaining on an upward trajectory. The Biohaven acquisition now adds a complementary, early-stage epilepsy asset to SK Biopharmaceuticals' already-proven commercial engine, further fueling the market's positive reaction. On the wider market front, the KOSPI turned higher today, rising by around 0.9%.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}